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ABSTRACT Duration of efficacy and prevalence of side-effects associated with GonaCon Immunocon-
traceptive Vaccine (GonaCon) in free-ranging female elk (Cervus elaphus) are unknown. In January 2008, we
captured 120mature female elk in RockyMountain National Park (CO, USA), determined pregnancy status,
and randomly assigned them to treated (n¼ 60; 1.5mL of GonaCon) or control (n¼ 60; 1.5mL of saline)
groups. During the following 3 winters we recaptured, collected blood for antibody concentrations, and
euthanized 10–20 elk in each group. At necropsy, we determined pregnancy and collected tissues from organs
associated with the hypothalamic–pituitary–gonadal axis. We relocated injection sites, collected muscle
tissue, and performed bacterial culture when inflammation was present. Proportion of pregnant elk among
control females ranged from 0.75 to 0.90. Proportion pregnant after treatment with GonaCon was 0.00 (95%
CI¼ 0.0–0.22) in year 1, 0.31 (CI¼ 0.09–0.61) in year 2, and 0.65 (CI¼ 0.41–0.85) in year 3. Antibody
concentrations were higher in non-pregnant than pregnant treated females. We found no antemortem
evidence of lameness or swelling at the injection site; however, at necropsy all treated females had
pyogranulomatous inflammation at the injection site. We observed no consistent changes within the
hypothalamic–pituitary–gonadal axis. We conclude that GonaCon is effective at reducing pregnancy for 1–2
years post-vaccination and is strongly associated with sterile inflammation at the site of injection. Similar to
other species, the vaccine is less effective in elk under free-ranging conditions than those in a captive
environment.  2014 The Wildlife Society.
KEY WORDS Cervus elaphus, elk, GonaCon, gonadotropin releasing hormone, immunocontraception, wildlife
fertility control.
Rocky Mountain elk (Cervus elaphus nelsoni) are resilient,
adaptable members of the cervid family. Much like white-
tailed deer (Odocoileus virginianus), they thrive in a variety of
habitats including the wildland–urban interface. When elk
become locally overabundant, this plasticity can lead to a
variety of human–wildlife conflicts and collateral effects,
which may be ecological, sociological, or political in scope
(Thompson and Henderson 1998). Fertility control is one
method, among a suite of management tools, which may
assist in mitigating these conflicts (Bradford and Hobbs
2008).
The idea and science of wildlife fertility control is not new.
For >4 decades practitioners have investigated the efficacy
and practicality of manipulating wildlife reproduction using a
variety of methods in a wide range of species (Fagerstone
et al. 2010); however, for a multitude of ecological and socio-
political reasons, wildlife contraception has not been widely
adopted as a means for population management (reviewed in
Powers 2011). Recently, extended-duration immunocon-
traception using the self-antigen, gonadotropin releasing
hormone (GnRH) has overcome some of the barriers to
successful application of a fertility control agent.
Gonadotropin-releasing hormone is a small protein
hormone naturally secreted in a variable pulsatile fashion
from the hypothalamus (Clarke and Cummins 1982). It
controls the reproductive hormone cascade that eventually
results in signaling at the gonad and ovulation in females
(Hazum and Conn 1988). A single vaccination against
GnRH, using GonaCon Immunocontraceptive Vaccine
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(GonaCon; National Wildlife Research Center, Fort
Collins, CO, USA; Miller et al. 2008), has been found to
diminish endocrine and ovarian function within the
hypothalamic–pituitary–gonadal axis in captive female elk
(Powers et al. 2011). Presumably through immuno-
neutralization, antibodies directed against GnRH prevent
or reduce GnRH stimulation at the anterior pituitary, reduce
gonadotropin release, and prevent ovulation. As antibodies
wane, females tend to return to fertility (Curtis et al. 2008,
Gionfriddo et al. 2011a, Powers et al. 2011).
Extended infertility (3 yr) using GonaCon has been
demonstrated in captive female elk (Killian et al. 2009,
Powers et al. 2011); however, efficacy is unknown under free-
ranging conditions. Vaccination of free-ranging white-tailed
deer revealed shorter duration of efficacy and a higher
apparent incidence of negative side-effects, such as injection-
site abscesses, than in captive deer (Curtis et al. 2008; Miller
et al. 2008; Gionfriddo et al. 2009, 2011a, b). The objective
of this study was to determine the efficacy of GonaCon to
reduce fertility in free-ranging female elk. We also sought to
document and describe potential side-effects associated with
vaccination.
STUDY AREA
This study was conducted in conjunction with, and used the
same animals as, those described by Monello et al. (2013).
We captured elk on their winter range within Rocky
Mountain National Park, Colorado, USA. Elk primarily
wintered in the eastern portion of the park and adjacent Estes
Valley, which included the Town of Estes Park, Colorado
(4082204400N, 10583203600W), between 2,500m and 2,800m
in elevation (previously described in Conner et al. [2007] and
Monello et al. [2013]).
Elk are seasonally polyestrous and breed during periods of
decreasing day length. InNorthAmerica, the peak of breeding
season occurs between mid-September and mid-October and
calving occurs from late May to early June after a gestation
period of approximately 255 days (Haigh and Hudson 1993).
Elk aremonotocous, nearly always giving birth to a single calf;
twinning is exceptionally rare (Haigh and Hudson 1993).
Intrinsic pregnancy rates during 2003–2004 in this elk
population were previously estimated to be between 0.82
and1.0(Conneretal.2007),whichwassimilar toratesreported
for other free-ranging elk (Cook et al. 2004, Sargeant and
Oehler 2007). This population was also habituated to the
presence of humans; thus, ground-darting on foot and from
vehicles was a feasible and effective method of capture.
MATERIALS AND METHODS
Animals and Treatment
This study was approved by the Colorado State University
Institutional Animal Care and Use Committee (no. 07-231-
01) and was conducted in conjunction with adaptive
management practices described in the Rocky Mountain
National Park Elk and Vegetation Management Plan
(National Park Service 2007). During January 2008, we
opportunistically selected and captured 120 mature adult (>2
yr) female elk using chemical immobilization and dart delivery
[detailed capture methods are described in Monello et al.
(2013)]. At the time of capture, we determined pregnancy
status using transrectal palpation (Greer and Hawkins 1967,
Hein et al. 1991), estimated body condition (1–5 scale; Cook
et al. 2001a, b; Conner et al. 2007), and collected 10mLwhole
blood via jugular venipuncture (BD Vacutainer SST; Becton
Dickinson and Co., Franklin Lakes, NJ).
We randomly allocated animals into 2 groups: treated and
control. We vaccinated treated females (n¼ 60) with
GonaCon (1.5mg GnRH conjugateþ adjuvant; 1.5mL),
and control females (n¼ 60) received physiologic saline
(0.9% NaCl; 1.5mL). While the animal was in sternal
recumbancy, we placed injections mid-way between the tuber
ischii of the caudal ischium and greater trochanter of the
femur using a hand-held luer-lock syringe and 18-gauge,
3.8-cm needle. To facilitate injection-site relocation at
necropsy, we measured (cm) and recorded the distance from
the greater trochanter to the injection site.
GonaCon was prepared as previously described (Miller
et al. 2008). The vaccine contained multiple synthetic copies
of GnRH coupled to a large immunogenic carrier protein
(Blue Carrier; Biosonda, Santiago, Chile) that was combined
with a water-in-oil adjuvant containing killedMycobacterium
avium ssp. avium (AdjuVac, National Wildlife Research
Center).
We fitted all experimental elk with very high-frequency
radiocollars (Advanced Telemetry Systems, Isanti, MN)
marked with individually identifiable black alphanumeric
codes on colored background (blue for saline—control,
yellow for GonaCon—treated; Conner et al. 2007). Color
codes were employed to avoid confusion when later culling
the animals and to prevent hunters from consuming treated
animals if they were harvested outside of the park. We
administered long-acting penicillin (6 million IU, SQ; Dura-
Pen; Duravet, Blue Springs, MO) to mitigate potential
infection associated with capture. Once all samples were
collected, we reversed the effects of immobilizing agents (as
described in Monello et al. [2013]).
Reproduction
We confirmed pregnancy status in January 2008 using serum
pregnancy-specific protein-B assays from blood collected at
the time of capture (Huang et al. 2000). During the
following 3 winters (Dec–Jan), we recaptured and euthanized
treated and control elk (2008–2009¼ 10 treated, 10 control;
2009–2010¼ 13 treated, 12 control; 2010–2011¼ 20
treated, 14 control). Additionally, one GonaCon treated
elk was euthanized in April 2009 due to unrelated
circumstances and her pregnancy status was included in
the data set. Pregnancy in euthanized elk was determined by
direct inspection of the uterus at necropsy. Capture and
sampling protocols were the same as above except that we
euthanized each animal using pentobarbital sodium and
phenytoin sodium (45mL IV; Euthasol; Virbac AH, Inc.,
Fort Worth, TX). We transported carcasses to the Colorado
State University Veterinary Diagnostic Laboratory and
performed complete necropsies. Prior to transport, we
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removed collars so the pathologist did not know treatment
status at the time of necropsy. We estimated the age of each
elk by removing a single central incisor at necropsy and
submitting it for dental cementum annuli analysis (Matson
Laboratory LLC, Milltown, MT; Hamlin et al. 2000).
Antibody Concentrations
We measured GnRH antibody concentrations (pmol 125I-
GnRH bound/mL of serum) using a previously described
radioimmunoassay technique (Powers et al. 2011).All samples
were run in a single batch. The intra-assay coefficient of
variation was 7.0%. We measured GnRH binding capacity
from serum samples collected prior to treatment and at the
time of euthanasia, 1–3 years post-vaccination.
Adverse Side-Effects
We confirmed survival status weekly throughout the study
using radiotelemetry. Additionally, we relocated each female
at least bi-monthly and observed the injection site from a
distance of approximately 20–100m using binoculars. We
noted obvious lameness and injection-site swelling or
discharge. Similarly, prior to darting and re-capture (2009–
2011), we observed each female at a distance of 10–40m for
evidence of changes in gait or lameness as well as injection-site
swelling or discharge. At the time of necropsy (approx. 2–6hr
post-euthanasia), we relocated the injection site, collected a
swab of the area if purulent inflammation was present, and
collected 5–20 g of affectedmuscle tissue, whichwas preserved
in 10% neutral buffered formalin. During the final 2 years, we
measured lesion length, height, and width (cm) and calculated
volume (cm3). In 77 of 79 necropsies, we collected and
preserved the draining internal iliac lymph node from the leg
containing the injection site. We collected sections of uterine
wall, cotyledon (if gravid), ovary (with corpus luteum, if
present), hypothalamus, and pituitary gland, and preserved all
tissues in formalin. Finally, we visually evaluated all major
organs including cardiovascular, respiratory, renal, immune,
and hepatic systems. If gross abnormalities were observed, we
collected tissue for histopathology.
We submitted swabs collected from the site of injection to
the Colorado State University Veterinary Diagnostic
Laboratory for aerobic, anaerobic, and mycobacterial culture.
We allowed all preserved tissues to fix for 1 week and used
standard histology techniques to paraffin embed, section, and
stain tissues. Sections of muscle taken from the injection site
were stained with Ziehl–Neelsen stain to identify acid-fast
microbial organisms such as mycobacteria. A veterinary
pathologist (T.R. Spraker) examined all slides for pathologic
changes in tissue architecture and evidence of inflammation.
Analysis
We used information-theoretic model selection to evaluate
the ability of treatment and individual characteristics to
explain the pregnancy status of adult female elk. To assess the
importance of these parameters on pregnancy, we developed
11 candidate models that included treatment group
(GonaCon-treated or saline control), time since injection
(yr of study), age, and body condition. A priori hypotheses
and model formulation was based on factors known to
influence pregnancy status in elk (Stewart et al. 2005), and
we examined both the additive and interactive effects of
study year and treatment and study year and body condition.
Intercept-only and global models were also included in
model selection procedures.
We used generalized linear models with a binomial
distribution and logit link for model selection (Hardin
and Hilbe 2007). Pregnancy status of each individual was the
sample unit. We conducted a goodness-of-fit test to assess
the ability of model parameters to explain pregnancy by
comparing the global model against the intercept-only model
(Franklin et al. 2000). We proceeded with model-selection
procedures only if global models provided a better fit than
intercept-only models (a¼ 0.05). We calculated Akaike’s
Information Criterion (corrected for small sample size;
AICc) and ranked the models based on differences between
the best approximating model and all other models (DAICc)
in the candidate set. Models with a DAICc value 2 of the
best-fitting model were considered to have substantial
empirical support as a best-fitting model. To better assess
model structure and factors, we calculated the overdispersion
factor of the best-fit model, model weight (i.e., the relative
likelihood that a particular model is the best-fit model), and
model-averaged estimates (95% unconditional confidence
interval [CI]) for the effect size of each parameter in the 95%
confidence set of models (Smodel wt  0.95; Burnham and
Anderson 2002).
We report pregnancy proportions, antibody concentra-
tions, lesion size, and body condition scores as arithmetic
means with 95% CI.
RESULTS
Vaccine Efficacy
At the time of initial capture and treatment application, the
proportion pregnant in GonaCon-vaccinated females was
0.85 (CI¼ 0.73–0.93) and in control females was 0.92
(CI¼ 0.82–0.97). During our study, proportion of pregnant
females in the treated group increased from 0.0 (CI¼ 0.0–
0.22) 1 year post-treatment to 0.65 (CI¼ 0.41–0.85) 3 years
post-treatment (Fig. 1). Proportion pregnant in the control
group varied from a low of 0.75 (CI¼ 0.43–0.95) to a high of
0.90 (CI¼ 0.56–1.00; Fig. 1).
Goodness-of-fit tests that compared the ability of the
global and intercept-only model to explain pregnancy were
significantly different (likelihood ratio x2¼ 37.65, df¼ 9,
P< 0.001). Only 2 models were considered to have
substantial support as the best-fit model for pregnancy
(DAICc of 0–2); both included the interaction treatment
year, and one also included body condition (Table 1;
overdispersion of best-fit model¼ 0.92). Model-averaged
estimates clearly indicated that the interactive effects of
treatment and year had the largest influence on pregnancy
status, with the greatest effects of vaccination occurring in
the first year of the study (Table 2 and Fig. 1). The effects of
vaccination persisted at a reduced level into the second year
of the study, but were absent by the third year, when the
pregnancy rate of treated elk more than doubled from the
prior year’s value (Table 2 and Fig. 1).
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Three-year mean serum GnRH antibody concentrations in
non-pregnant GonaCon-treated females (28 pmol/mL; CI
¼ 27–29) were higher than in pregnant treated females
(7 pmol/mL; CI¼ 6–8; Fig. 2). There was no evidence of
GnRH antibodies in pretreatment serum samples from any
animal (data not shown) or post-treatment control serum
samples (Fig. 2). In all GonaCon-treated females, regardless
of pregnancy status, GnRH antibody concentrations were
highest the first year after vaccination at 29 pmol/mL
(CI¼ 22–37) and declined to a mean of 13 pmol/mL
(CI¼ 7–18) by the third year post-treatment.
Body condition had little to no effect on pregnancy
proportions (Table 2). Mean body condition 1–3 years post-
treatment was 3.01 (CI¼ 2.77–3.24) in control females and
3.19 (CI¼ 2.97–3.41) in GonaCon-treated females.
Adverse Side-Effects
We did not observe any lameness or visible lesions at the site
of injection prior to recapture and euthanasia. We could not
detect any abnormalities externally with direct palpation of
the injection site prior to euthanasia. In contrast, at the time
of necropsy, all 43 GonaCon-treated females had grossly
visible subcutaneous or intramuscular lesions at the injection
site. Lesion size varied greatly from 1 cm3 to 492 cm3. Mean
lesion size in treated animals was 101 cm3 (CI¼ 2–199) 2
years post-treatment and 130 cm3 (CI¼ 87–173) 3 years
post-treatment. Most contained purulent material that
varied in consistency from liquid to caseate. Lesions varied
from one large mass to complex multi-loculated granulomas
that dissected along tissue planes. Granulomatous myositis
tended to be encapsulated within a thick wall of fibroplasia
with extensive collagen deposition and inflammatory cell
infiltrates including macrophages, lymphocytes, plasma cells,
and multinucleated giant cells.
We cultured 33 of 43 injection-site lesions for anaerobic
and aerobic bacteria, including mycobacteria. Approximately
6% (2/33) had microbial growth. Light growth of
Staphylococcus sp. and non-hemolytic Streptococcus sp. were
each cultured once. No mycobacteria species were cultured.
We found acid-fast organisms consistent with mycobacteria
twice within fixed tissues taken from injection sites. On 3
occasions, the draining internal iliac lymph nodes had similar
pyogranulomatous inflammation as that seen at the injection
site, though not to the same severity. Histology of muscle
tissue collected from the area of the injection sites of control
females was within normal limits and we did not find
evidence of inflammatory processes.
We did not identify any consistent lesions in tissues from
the hypothalamic–pituitary–gonadal axis of treated or control
elk. Hypothalami were within normal limits and showed no
evidence of inflammatory cell infiltrates. We identified a
granulosa cell tumor in the ovary of one treated female and an
ovarian teratoma and a cystic ovary in 2 separate control
females. All ovarian pathology was considered incidental.
DISCUSSION
A single vaccination against GnRH using GonaCon during
mid-gestation successfully prevented pregnancy the follow-
ing year, and was moderately effective 2 years after
1 yr 2 yr 3 yr
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Figure 1. Proportion (95% CI) of female elk sampled at RockyMountain
National Park, Colorado that were pregnant prior to treatment (January
2008) with either GonaCon Immunocontraceptive Vaccine (treated group)
or saline (control group) and pregnancy proportions 1–3 years post-
treatment (winters of 2009–2011). Sample sizes at the time of treatment
were 60/group and in each year after ranged from 10 to 20 elk/group; no elk
were sampled more than once post-injection. Immunocontraception was
effective for 2 years post-treatment but pregnancy proportions between
treated and control elk were similar 3 years post-treatment.
Table 1. Rankings of a priori models used to determine pregnancy status in female elk at Rocky Mountain National Park, Colorado subjected to treatment
with a contraceptive agent (GonaCon Immunocontraceptive Vaccine, n¼ 44) or a control injection of saline (n¼ 36). Rankings are based on generalized
linear models with a binomial distribution and logit identity. Contraceptive treatment, year since treatment was given, and the interaction between treatment
and year were the most important factors in predicting pregnancy.
Model loge(L) K AICc DAICc vi
Treatment yearþ treatmentþ year 36.71 6 86.58 0.00 0.58
Treatment yearþ conditionþ treatmentþ year 36.16 7 87.87 1.29 0.30
Treatmentþ yearþ condition 39.91 5 90.62 4.05 0.08
Global model 35.40 10 93.98 7.40 0.01
Treatmentþ condition 44.26 3 94.84 8.26 0.01
Treatment 45.57 2 95.30 8.72 0.01
Treatmentþ conditionþ age 43.60 4 95.74 9.16 0.01
Treatmentþ age 45.34 3 96.99 10.42 0.00
Treatmentþ year 51.30 3 108.91 22.34 0.00
Intercept-only model 54.22 1 110.49 23.91 0.00
Yearþ condition 51.05 4 110.63 24.06 0.00
Year conditionþ yearþ condition 51.49 4 111.52 24.94 0.00
Condition 53.83 2 111.82 25.24 0.00
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vaccination, but there were no clear differences in the treated
and control groups by the third year of the study. Similar
work in captive elk using the same vaccine formulation found
that GonaCon reduced pregnancy by 50–100% for up to 3
years post-treatment (Powers et al. 2011), suggesting that
this vaccine has a reduced duration of efficacy in free-ranging
elk. This is consistent with our anti-GnRH antibody
concentrations, which were neither as robust nor as persistent
in free-ranging elk as captive elk (Powers et al. 2011).
This finding is also consistent with effects of GonaCon
observed in captive versus free-ranging white-tailed deer
(Miller et al. 2008; Gionfriddo et al. 2009, 2011a). No
definitive cause for differences in efficacy between captive
and free-ranging populations has been determined; however,
it has been suggested that differences in immune-response
and therefore efficacy may be attributable to variance in
nutritional status, micro- or macro-parasite load or exposure,
previous pathogen exposure, environmental contact with
mycobacteria, or other sources of physiologic stress (Tizard
1982, Gionfriddo et al. 2011b, Powers et al. 2011). All of
these factors have the potential to potentiate or inhibit the
response to a novel antigen such as GnRH coupled to a
mollusk protein in the GonaCon vaccine. Thus, free-ranging
cervids, which generally have a lower plane of nutrition and
increased number of stressors compared with captive wildlife,
may not produce as vigorous an immune response. This
hypothesis is supported by prior work that found diminished
and less persistent GnRH antibody concentrations in free-
ranging versus captive white-tailed deer (Miller et al. 2008,
Gionfriddo et al. 2011a) and is in accordance with our
current antibody findings.
Although there were no outwardly visible signs of lameness
or dysfunction associated with vaccination, every treated
animal had grossly evident inflammation at the site of
injection, which varied in size and shape and contained up to
500mL of suppuration. There was no evidence to suggest
that injection-site lesions decreased in size or severity
between years. This is not surprising given the vaccine is
composed of non-biodegradable mineral oil and contains
strongly immunogenic-killed mycobacteria similar to vac-
cines made with Freund’s complete (FCA) and modified
Freund’s complete (mFCA) adjuvants (Lyda et al. 2005,
Powers et al. 2007, Roelle and Ransom 2009, Ransom et al.
2011). Other studies using GnRH vaccines or porcine zona
pellucida vaccines (another type of immunocontraceptive
vaccine), which use similar mycobacterial emulsion type
adjuvants, did not identify injection-site lesions at the
prevalence we did in this investigation (Curtis et al. 2002,
Lyda et al. 2005, Roelle and Ransom 2009, Powers et al.
2011). However, many studies did not necropsy animals
post-vaccination, and in most cases exact injection-site
locations were not determined to ensure accurate reassess-
ment. In all studies where post-mortem examinations were
performed, prevalence of injection-site inflammation and
abscesses were higher than those that were clinically apparent
antemortem (Curtis et al. 2007, 2008; Powers et al. 2007;
Gionfriddo et al. 2009, 2011b). Therefore, it should not be
inferred that lack of clinically evident antemortem abscess
Table 2. Model-averaged estimates of parameter effect size for those included in the 95% confidence set of models used to determine pregnancy status in
female elk at Rocky Mountain National Park, Colorado subjected to treatment with a fertility control agent (GonaCon Immunocontraceptive Vaccine,
n¼ 44) or a control injection of saline (n¼ 36). Estimates are based on generalized linear models with a binomial distribution and logit identity.
Parameter Estimate Unconditional SE 95% unconditional CI
Treatment year 1 4.18 1.55 7.21, 1.14
Treatment year 2 2.64 0.98 4.56, 0.72
Treatment year 3 1.22 0.90 2.99, 0.55
No treatment year 1 0.37 1.31 2.19, 2.93
No treatment year 2 0.64 1.02 2.64, 1.36
No treatment year 3 0.00 0.00
Treatment 2.54 0.67 3.85, 1.24
No treatment 0.00 0.00
Year 1 1.97 0.75 3.45, 0.049
Year 2 1.31 0.67 2.62, 0.01
Year 3 0.00 0.00
Body condition 0.50 0.43 0.39, 1.39
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Figure 2. Yearly mean gonadotropin releasing hormone antibody concen-
trations presented as pmol of 125I-GnRH bound (e.g., antibody binding
capacity) in 1mL of serum (95% CI), collected from female elk treated in
January 2008 with either GonaCon Immunocontraceptive Vaccine (treated
group) or saline (control group) at Rocky Mountain National Park,
Colorado. Closed diamonds (^) represent non-pregnant—treated females
(vaccine success); open diamonds (^) represent pregnant treated females
(vaccine failure); and open squares (&) represent control females (both
pregnant and non-pregnant). In year 1 no treated females were pregnant.
Error bars are too small to present for yearly means in control females.
Higher antibody concentrations were associated with contraception success.
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formation means that these immunocontraceptive vaccines
do not cause significant inflammation at the site of injection.
Additional post-mortem studies across multiple species are
required to determine whether this is a general trend among
immunocontraceptive vaccines.
Injection-site lesions were most often sterile. Although
bacteria were occasionally cultured from swabs taken of
purulent inflammation at the site of injection, we postulate
that these were surface contaminants. Non-hemolytic
Streptococcus sp. and Staphylococcus sp. are common mamma-
lian skin commensal organisms (Hirsh and Biberstein 2004a,
b). Given clean but not sterile collection techniques at the
time of necropsy, it is not surprising that we could have
inadvertently introduced small amounts of contamination at
this time. Additionally, cells found at injection sites were
characteristic of granulomatous inflammation, which is
classically associated with the presence of mycobacteria
(Ackermann 2007). It is highly unlikely that the vaccine itself
was responsible for bacterial growth at the site of injection.
We suggest, as previously reported by others (Curtis et al.
2008, Gionfriddo et al. 2011b), that the combination of
killed mycobacteria and a non-biodegradable mineral oil
created a long-lasting depot of immune-stimulating antigen
that continued to attract macrophages and lymphocytes and
incite formation of persistent pyogranulomatous inflamma-
tion. Despite substantial injection-site lesions in every
animal, we did not see clinical evidence of altered locomotion
or detriment to the general health and fitness of treated elk.
The cumulative effects of revaccination are unknown at this
time; however, the potential exists for more intense immune
reactions with additional doses of mycobacterial adjuvant
once the animal has been primed with an initial dose
(Broderson 1989). Additional studies, particularly on the
effects of revaccination, are needed to understand the
potential range of effects that could occur with long-term
management programs that seek to use vaccines such as
GonaCon to regulate population size.
It has been suggested that wildlife fertility control offers an
alternative management technique to lethal removal.
Although our study demonstrates that immunocontracep-
tion using GonaCon can decrease fertility of individual
animals, there is little empirical evidence in the literature to
indicate that fertility control techniques can be effectively
applied on a scale large enough to limit population growth
rates of free-ranging cervids, especially when immigration or
emigration are important drivers of population size (Merrill
et al. 2006, Ransom et al. 2014). Jurisdictional boundaries
rarely contain entire populations of highly mobile and often
migratory cervids, which poses a significant challenge for
treating sufficient proportions of a functionally continuous
population unless all affected wildlife management agencies
are in agreement that this is a preferred management
strategy. There are substantial limitations to the population-
level efficacy of fertility control even within closed
populations of cervids with high reproductive and survival
rates (Hobbs et al. 2000). Additionally, there are potentially
large ecological effects—such as changes to natural selection,
effects on social structures and reproductive behavior, timing
of mating and birthing seasons, changes to longevity, and
effects on migratory or movement patterns—that still need
to be examined in free-ranging populations prior to use as a
management tool (Cooper 2004, Powers 2011, Ransom et al.
2014).
Our data indicate that a single injection of GonaCon will
significantly decrease reproduction in free-ranging female
elk. However, this does not resolve the more important
question, which asks whether this equates to a viable tool for
managing human–wildlife conflicts in the future. Only by
engaging in socio-political discourse with interested stake-
holder groups informed by knowledge of population-level
effects will we discover whether the costs and benefits of
wildlife fertility control are adequately balanced to seriously
consider contraceptive technology a practical wildlife
management alternative.
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